In contrast, MTC is caused by the activation of the RET gene through a gain-of-function, and C620R, which is recognized as a gain-of-function type in the ATA risk classification, has been reported to be inactivated by loss of cell surface expression of the RET protein in vivo [9]. Here, RET is linked to medullary thyroid gland carcinoma.